Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Transaction in Own Shares

11th Dec 2025 07:00

RNS Number : 1001L
CVS Group plc
11 December 2025
 

11 December 2025

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

 

CVS announces that on 10 December 2025 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").

 

Date of purchase:

10/12/2025

Aggregate number of Ordinary Shares purchased:

24,425

Lowest price paid per share (GBp):

1,218.00

Highest price paid per share (GBp):

1,236.00

Volume weighted average price paid per share (GBp):

1,228.06

CVS intends to cancel all of the purchased Ordinary Shares.

 

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,891,292 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

 

The total number of voting rights in CVS is therefore 70,891,292 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Since the commencement of the Share Buyback Programme, the Company has repurchased 849,491 Ordinary Shares in aggregate at a weighted average price of 1,215.79 pence per share.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

 

Individual transactions:

 

Number of

Ordinary Shares purchased

Transaction price (GBp share)

Time of

transaction (UK Time)

Transaction

reference number

Trading Venue

 

632

1236

10/12/2025 09:03:02

1348989714704231

XLON

451

1236

10/12/2025 09:03:04

1348989714704235

XLON

139

1232

10/12/2025 09:32:26

1348989714706519

XLON

716

1232

10/12/2025 09:32:29

1348989714706527

XLON

702

1232

10/12/2025 10:04:10

1348989714708739

XLON

735

1230

10/12/2025 10:05:00

1348989714708840

XLON

737

1234

10/12/2025 10:41:39

1348989714711036

XLON

749

1234

10/12/2025 10:41:39

1348989714711040

XLON

71

1234

10/12/2025 10:41:44

1348989714711042

XLON

772

1232

10/12/2025 10:42:01

1348989714711060

XLON

34

1232

10/12/2025 10:44:01

1348989714711276

XLON

183

1232

10/12/2025 10:45:00

1348989714711369

XLON

60

1232

10/12/2025 10:45:00

1348989714711370

XLON

809

1234

10/12/2025 11:03:49

1348989714712577

XLON

848

1234

10/12/2025 11:23:22

1348989714713696

XLON

200

1234

10/12/2025 11:24:53

1348989714713773

XLON

869

1232

10/12/2025 11:27:19

1348989714713967

XLON

128

1232

10/12/2025 11:38:26

1348989714714838

XLON

292

1232

10/12/2025 11:38:26

1348989714714839

XLON

98

1232

10/12/2025 11:38:26

1348989714714840

XLON

108

1232

10/12/2025 11:41:33

1348989714715129

XLON

344

1232

10/12/2025 11:41:33

1348989714715130

XLON

229

1232

10/12/2025 11:43:56

1348989714715381

XLON

897

1232

10/12/2025 11:45:06

1348989714715526

XLON

900

1232

10/12/2025 11:55:24

1348989714716317

XLON

583

1232

10/12/2025 11:55:24

1348989714716322

XLON

462

1232

10/12/2025 11:55:57

1348989714716361

XLON

246

1232

10/12/2025 11:55:57

1348989714716362

XLON

415

1232

10/12/2025 11:56:02

1348989714716395

XLON

189

1232

10/12/2025 12:02:20

1348989714717078

XLON

150

1230

10/12/2025 12:02:20

1348989714717083

XLON

228

1230

10/12/2025 12:02:20

1348989714717084

XLON

171

1226

10/12/2025 12:03:01

1348989714717176

XLON

607

1226

10/12/2025 12:03:01

1348989714717177

XLON

775

1224

10/12/2025 12:12:16

1348989714717969

XLON

522

1224

10/12/2025 12:16:59

1348989714718444

XLON

751

1224

10/12/2025 12:18:43

1348989714718586

XLON

554

1224

10/12/2025 12:18:43

1348989714718591

XLON

423

1218

10/12/2025 12:20:08

1348989714718770

XLON

318

1218

10/12/2025 12:20:08

1348989714718771

XLON

182

1220

10/12/2025 12:27:25

1348989714719216

XLON

552

1220

10/12/2025 12:27:25

1348989714719217

XLON

6

1220

10/12/2025 12:38:53

1348989714719982

XLON

7

1220

10/12/2025 12:38:53

1348989714719983

XLON

3

1220

10/12/2025 12:38:53

1348989714719984

XLON

542

1220

10/12/2025 12:42:01

1348989714720209

XLON

182

1220

10/12/2025 12:42:01

1348989714720210

XLON

44

1222

10/12/2025 13:04:03

1348989714721785

XLON

10

1222

10/12/2025 13:04:03

1348989714721786

XLON

96

1222

10/12/2025 13:04:03

1348989714721787

XLON

48

1222

10/12/2025 13:04:03

1348989714721788

XLON

684

1224

10/12/2025 13:45:41

1348989714725418

XLON

509

1224

10/12/2025 13:45:41

1348989714725422

XLON

11

1224

10/12/2025 13:45:41

1348989714725423

XLON

200

1222

10/12/2025 14:06:54

1348989714727650

XLON

699

1220

10/12/2025 14:22:33

1348989714728978

XLON

140

1218

10/12/2025 14:22:35

1348989714728984

XLON

714

1218

10/12/2025 14:34:55

1348989714731296

XLON

204

1218

10/12/2025 14:36:01

1348989714731495

XLON

67

1218

10/12/2025 14:36:01

1348989714731496

XLON

258

1218

10/12/2025 14:39:12

1348989714732195

XLON

451

1224

10/12/2025 15:09:05

1348989714738505

XLON

291

1224

10/12/2025 15:09:05

1348989714738506

XLON

237

1222

10/12/2025 15:17:32

1348989714740270

XLON

96

1222

10/12/2025 15:21:54

1348989714741540

XLON

72

1222

10/12/2025 15:26:49

1348989714742410

XLON

23

1220

10/12/2025 15:35:04

1348989714743809

XLON

 

 

Contacts

CVS Group plc via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

 

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

 

Camarco (Financial PR) [email protected]

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSGPGBCPUPAPGU

Related Shares:

CVS Group
FTSE 100 Latest
Value9,649.03
Change-54.13